Quick Answer
Enliven Therapeutics, Inc. reported Stockholders Equity of $459.60 million for the year ending 2025.
- Enliven Therapeutics, Inc. showed an increase of +48.3% in Stockholders Equity from 2024 to 2025.
- This data is from Enliven Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$30.42 million | Q2 2019: -$35.62 million | Q3 2019: -$41.90 million | Q1 2020: $105.19 million | Q2 2020: $106.30 million | Q3 2020: $94.70 million | Q1 2021: $75.59 million | Q2 2021: $64.97 million | Q3 2021: $99.37 million | Q1 2022: -$50.61 million | Q2 2022: -$58.71 million | Q3 2022: -$68.10 million | Q1 2023: $291.42 million | Q2 2023: $278.99 million | Q3 2023: $261.75 million | Q1 2024: $317.71 million | Q2 2024: $304.93 million | Q3 2024: $288.40 million | Q1 2025: $288.30 million | Q2 2025: $488.47 million | Q3 2025: $476.12 million.
- Over the full 8 years of available data (2018 to 2025), Enliven Therapeutics, Inc.'s Stockholders Equity has grown by 1,846.5%.
- Historical annual values: Fiscal year 2025: $459.60 million | Fiscal year 2024: $309.85 million | Fiscal year 2023: $245.91 million | Fiscal year 2022: -$76.83 million | Fiscal year 2021: -$42.89 million | Fiscal year 2020: $84.44 million | Fiscal year 2019: -$48.85 million | Fiscal year 2018: -$26.32 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: